Takeda’s Post

Thailand has the second-largest pharmaceutical market in Southeast Asia after Indonesia. According to the market research company BMI, sales are set to rise from 3.8 billion US dollars (US$) in 2022 to 9.4 billion in 2032, driven by an ageing population, higher income and the expansion of healthcare. But why foreign pharmaceutical manufacturers hardly produce or be involved in research and development in Thailand? Read more from an article written by Mr. Thomas Hundt, Director of Thailand, Cambodia, Myanmar, and Laos at Germany Trade & Invest (GTAI), here>> https://lnkd.in/gZNYjP3n #GTCCUPDATEMagazine #PharmaceuticalIndustry #Pharma #Trends #healthcare #GTCC #AHKThailand #PartnerForSuccess #PartnerInThailand #PartnerWorldwide

It's interesting that The Lancet addresses housing as a key social determinant of health. We briefly touched on this in our 2019 report on collaboration in the pharmaceutical industry, where we highlighted this issue (page 19 of the attached). As always, I'm keen to hear innovative strategies industry might adopt to combat preventable health issues proactively. https://lnkd.in/esDR2cED

Here is a good article in Chain Drug Review.

🌟 Breaking News in Medical Science! 🌟 Exciting developments from Denali Therapeutics. as they unveil groundbreaking results in the fight against mucopolysaccharidoses (MPS)! 🧬✨ 1️⃣ MPS II & Tividenofusp Alfa (DNL310) Update: After 104 weeks of treatment, patients show remarkable improvement and stabilization, marking a significant milestone in MPS II (Hunter Syndrome) therapy. 🚀💪 The treatment has normalized CSF heparan sulfate and achieved a robust, sustained reduction in neurofilament light chain (NfL), indicating a leap forward in neurodegenerative disease management. 🧠🔬 2️⃣ Launch of DNL126 (ETV:SGSH) for MPS IIIA: Denali kicks off dosing in the Phase 1/2 study of DNL126, targeting MPS IIIA (Sanfilippo Syndrome Type A). Early mouse model studies show promising reductions in heparan sulfate, correlating with cognitive function improvements. 🐁💡 🔍 Why It Matters: Innovation at its Best: Denali’s BBB-crossing enzyme replacement therapies offer new hope, tackling both brain and physical symptoms of MPS diseases. 🌉💊 Community and Science Unite: Collaborative efforts aim for swift approval, bringing new treatment options closer to reality for MPS families. 🤝❤️ 🌈 Looking Ahead: With continued global collaboration and innovative research, Denali is on the fast track to revolutionizing treatment options for MPS diseases, aiming to enhance quality of life for affected individuals and their families. 🌍🙌 Stay tuned for more updates in this transformative journey! 📢 #MPSII #MPSIIIA #TividenofuspAlfa #DNL126 #DenaliTherapeutics #NeurodegenerativeDiseases #InnovativeTherapies #HopeForMPS #ScienceNews #MedicalAdvancements 🌟🔬🧬

#Biosimilars make it possible for more patients to receive care and patients have received 495 million more days of therapy because of #biosimilar competition. Still—more work needs to be done! To further increase patient access, policymakers must reduce the cost of development and ensure more adoption of lower-priced biosimilars. This will enable healthy competition and lower prices for patients! More in our #GRxBiosimsSavingsReport: https://lnkd.in/eJsmy6p5 Association for Accessible Medicines

🌍 Strategic Leadership in European Plasma Collection: A Call to Action for Regulators 🌍 Addressing the critical insufficiency in plasma collection within the European Union demands a strategic response. It's evident that the current reliance on third-country sources, with nearly 40% of required plasma sourced from the United States (according to PPTA Europe and reposted by several others), poses a significant risk to the sustainability of the EU supply chain . . . not a favorable position to remain in when pandemics and wars can emerge. This becomes especially critical when considering patients' dependence on plasma-derived medicines (PDMPs), compelling us to craft an improved source plasma solution in the EU that prioritizes patient health. In navigating this landscape it's clear a pragmatic and viable approach needs to be implemented without further delay. We must strategically design and implement new evidence-based policies aimed at not only boosting plasma collection within the rest of the EU, but also continue to protect the proven methods that underpin our current collection processes within the existing four EU countries. As a seasoned plasma procurement leader who has toured EU plasma donation centers of which are voluntarily and enthusiastically visited by remunerated donors, I have been impressed by the quality systems designed for donor safety and product quality, as well as the dignity and comfort afforded to these generous donors. Our commitment to the health and welfare of patients relying on plasma-derived therapies necessitates a comprehensive strategy. It involves expanding domestic plasma collection capabilities at the regional and national levels, and aligning with the escalating global clinical demand for PDMPs. By doing so, we not only address the immediate challenges highlighted in the original post by PPTA Europe but also proactively meet the evolving needs of patients who depend on these life-saving treatments. Advocating for #EUNeedsMorePlasma is not just a rallying cry; it's a strategic imperative. EU regulators owe it to their patient-citizens to safeguard and enhance accessibility to plasma-derived therapies by evolving remunerated plasma donation programs throughout the entire EU. Thoughtful, evidence-based regulations should encourage remunerated plasma donations, aligning with our duty to prioritize patient well-being and fortify the foundation of the EU healthcare systems. #EURegulations #PatientAccess #EvidenceBasedHealthcare 🌐 #PlasmaDonationEU #PatientWellbeing #HealthcareInnovation #LifeSciencesLeadership #EURegulations #EvidenceBasedHealthcare #RemuneratedPlasmaDonations #PatientAccess #PublicHealthEU #SoHO 🌐

The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZll60 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1

Deeper Data. Better Outcomes. Focusing on long-term care can significantly benefit underrepresented patients and vulnerable populations by improving access to therapies and coordinating care, leading to better outcomes. Learn more: https://lnkd.in/eRuphcNT #LongTermCare #Biopharmaceuticalnnovation #SilverSurge #LifeSciences

Our recent deep dive into the impact of GLP-1 on pharma and medtech revealed some eye-opening insights: In specific therapeutic domains, we identified over 20% of revenue at risk. When we turned our focus to US providers, we uncovered a staggering 60% profit risk. Our report, based on the latest medical research, highlights key strategic steps to reduce the impact of this looming threat. What should we look at next? Authors: Chris Paddison, Betty Pio, Cian Wade, and Amelia Whitworth